Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianwei Qutong Wan is a Traditional Chinese Medicine (TCM) developed by Hunan Fangsheng Pharmaceutical for the treatment of chronic non-atrophic gastritis. Approved by the China National Medical Products Administration (NMPA) in December 2023 as a Class 1.1 innovative Chinese medicine, it is indicated for patients exhibiting symptoms such as epigastric pain, fullness, and acid reflux associated with stomach-qi deficiency and stagnation of qi and blood. The formulation consists of multiple herbal extracts that work synergistically to invigorate the stomach, regulate qi, and alleviate pain. Clinical trials have shown that the drug effectively improves gastric mucosal health and provides symptomatic relief, offering a standardized TCM therapeutic option for chronic gastric conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jianwei Qutong Wan.